A Research Study Looking at How Victoza® Works in People With Type 2 Diabetes in Iran, Followed in Local Clinical Routine

CompletedOBSERVATIONAL
Enrollment

839

Participants

Timeline

Start Date

March 10, 2019

Primary Completion Date

October 21, 2020

Study Completion Date

October 21, 2020

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Liraglutide

Patients will be treated according to the Iranian label for Victoza®, following routine clinical practice and at the discretion of the study doctor. The study doctor will determine the intended maintenance dose of Victoza®, as well as any changes to the maintenance dose thereafter. Patients will be treated according to the Iranian label for Victoza®, following routine clinical practice and at the discretion of the study doctor. The study doctor will determine the intended maintenance dose of Victoza®, as well as any changes to the maintenance dose thereafter. The physician's decision to initiate treatment with Victoza® is clearly separate from the opportunity to include the patient in the study.

Trial Locations (16)

Unknown

Novo Nordisk Investigational Site, Ahvāz

Novo Nordisk Investigational Site, Ardabil

Novo Nordisk Investigational Site, Babol

Novo Nordisk Investigational Site, Gorgan

Novo Nordisk Investigational Site, Hamadan

Novo Nordisk Investigational Site, Hormozgan

Novo Nordisk Investigational Site, Isfahan

Novo Nordisk Investigational Site, Islamshahr

Novo Nordisk Investigational Site, Karaj

Novo Nordisk Investigational Site, Kerman

Novo Nordisk Investigational Site, Mashahd

Novo Nordisk Investigational Site, Mashhad

Novo Nordisk Investigational Site, Sari

Novo Nordisk Investigational Site, Shiraz

Novo Nordisk Investigational Site, Tehran

Novo Nordisk Investigational Site, Yazd

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY